Immune Thrombocytopenic Purpura

Bussel, 2006, AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP, N Engl J Med, 355, 1672, 10.1056/NEJMoa054626 Bussel, 2006, Analysis of bleeding in patients with immune thrombocytopenic purpura (ITP): a randomized, double-blind, placebo controlled trial of eltrombopag, an oral platelet growth factor, Blood, 108, 475, 10.1182/blood.V108.11.475.475 Kuhne, 2006, Idiopathic thrombocytopenic purpura in childhood: controversies and solutions, Pediatr Blood Cancer, 47, 650, 10.1002/pbc.20973 Ruggeri, 2006, Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from literature analysis, Pediatr Blood Cancer, 47, 653, 10.1002/pbc.20983 Zeller, 2005, Chronic idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease, Acta Paediatr, 94, 178, 10.1080/08035250410025294 Hedman, 1997, Prevalence and treatment of chronic idiopathic thrombocytopenic purpura of childhood in Sweden, Acta Paediatr, 86, 226, 10.1111/j.1651-2227.1997.tb08876.x Segal, 2006, Prevalence of immune thrombocytopenia: analyses of administrative data, J Thromb Haemost, 4, 2377, 10.1111/j.1538-7836.2006.02147.x Kuhne, 2001, Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study, Lancet, 358, 2122, 10.1016/S0140-6736(01)07219-1 Bolton-Maggs, 1997, Assessment of UK practice for management of acute childhood idiopathic thrombocytopenic purpura against published guidelines, Lancet, 350, 620, 10.1016/S0140-6736(97)04143-3 Harrington, 1951, Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura, J Lab Clin Med, 38, 1 Harrington, 1953, Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura, Ann Intern Med, 38, 433, 10.7326/0003-4819-38-3-433 McMillan, 2003, Antiplatelet antibodies in chronic adult immune thrombocytopenic purpura: assays and epitopes, J Pediatr Hematol Oncol, 25, S57, 10.1097/00043426-200312001-00013 Cines, 2002, Immune thrombocytopenic purpura, N Engl J Med, 346, 995, 10.1056/NEJMra010501 Olsson, 2003, T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura, Nat Med, 9, 1123, 10.1038/nm921 Sayeh, 2004, IgG antiplatelet immunity is dependent on an early innate natural killer cell-derived interferon-gamma response that is regulated by CD8+ T cells, Blood, 103, 2705, 10.1182/blood-2003-10-3552 Panitsas, 2004, Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response, Blood, 103, 2645, 10.1182/blood-2003-07-2268 McMillan, 2004, Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP, Blood, 103, 1364, 10.1182/blood-2003-08-2672 Ballem, 1987, Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance, J Clin Invest, 80, 33, 10.1172/JCI113060 Houwerzijl, 2004, Ultrastructural study shows morphological features of apoptosis and paraapoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura, Blood, 103, 500, 10.1182/blood-2003-01-0275 Chang, 2003, Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro, Blood, 102, 887, 10.1182/blood-2002-05-1475 Gernsheimer, 2002, Pathophysiology and thrombokinetics in autoimmune thrombocytopenia, Blood Rev, 16, 7, 10.1054/blre.2001.0171 Kuter, 1995, The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit, Blood, 85, 2720, 10.1182/blood.V85.10.2720.bloodjournal85102720 Aledort, 2004, Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies, Am J Hematol, 76, 205, 10.1002/ajh.20104 Musaji, 2004, Exacerbation of autoantibody-mediated thrombocytopenic purpura by infection with mouse viruses, Blood, 104, 2102, 10.1182/blood-2004-01-0310 Li, 2005, Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia, Blood, 106, 572, 10.1182/blood-2005-01-0243 Chia, 1998, Characterization of HIV-1-specific antibodies and HIV-1-crossreactive antibodies to platelets in HIV-1-infected haemophiliac patients, Br J Haematol, 103, 1014, 10.1046/j.1365-2141.1998.01116.x Kuwana, 2006, Helicobacter pylori and immune thrombocytopenic purpura: unsolved questions and controversies, Int J Hematol, 84, 309, 10.1532/IJH97.06188 Michel, 2004, Does helicobater pylori initiate or perpetuate immune thrombocytopenic purpura?, Blood, 103, 890, 10.1182/blood-2003-03-0900 Voulgaropoulou, 2000, Productive infection of CD34+-cell-derived megakaryocytes by X4 and R5 HIV-1 isolates, Virology, 269, 78, 10.1006/viro.2000.0193 Karpatkin, 1990, HIV-1-related thrombocytopenia, Hematol Oncol Clin North Am, 4, 193, 10.1016/S0889-8588(18)30513-6 Pivetti, 1996, High prevalence of autoimmune phenomena in hepatitis C virus antibody positive patients with lymphoproliferative and connective tissue disorders, Br J Haematol, 95, 204, 10.1046/j.1365-2141.1996.7542376.x Rajan, 2005, Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombcytopenic purpura, Br J Haematol, 129, 818, 10.1111/j.1365-2141.2005.05542.x Kodama, 2007, Immune response to CagA protein is associated with improved platelet count after helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura, Helicobacter, 12, 36, 10.1111/j.1523-5378.2007.00477.x Franchini, 2003, Helicobacter pylori eradication in adults with idiopathic thrombocytopenic purpura, Am J Med, 114, 420, 10.1016/S0002-9343(03)00055-X Pegels, 1982, Pseudothrombocytopenia: an immunologic study on platelet antibodies dependent on ethylene diamine tetra-acetate, Blood, 59, 157, 10.1182/blood.V59.1.157.157 Michel, 2005, Prognostic relevance of large-platelet counts in patients with immune thrombocytopenic purpura, Haematologica, 90, 1715 George, 1996, Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American society of hematology, Blood, 88, 3, 10.1182/blood.V88.1.3.3 Briggs, 2000, New quantitative parameters on a recently introduced automated blood cell counter - the XE-2100, Clin Lab Haematol, 22, 345, 10.1046/j.1365-2257.2000.00330.x Briggs, 2006, Immature platelet fraction measurement: a future guide to platelet transfusion requirement after haematopoietic stem cell transplantation, Transfus Med, 16, 101, 10.1111/j.1365-3148.2006.00654.x Briggs, 2004, Assessment of immature platelet fraction (IPF) in peripheral thrombocytopenia, Br J Haematol, 126, 93, 10.1111/j.1365-2141.2004.04987.x Psaila, 2006, Insights into therapeutic mechanisms: measuring the immature platelet fraction (IPF) describes response to treatment in immune thrombcytopenic purpura, Blood, 208, 1070, 10.1182/blood.V108.11.1070.1070 Zhou, 2007, Health-related quality of life measured by the short form 36 in immune thrombocytopenic purpura: a cross-sectional survey in China, Eur J Haematol, 78, 518, 10.1111/j.1600-0609.2007.00844.x Cines, 2005, How I treat idiopathic thrombocytopenic purpura (ITP), Blood, 106, 2244, 10.1182/blood-2004-12-4598 2003, British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy, Br J Haematol, 120, 574, 10.1046/j.1365-2141.2003.04131.x Mazzucconi, 2007, Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience, Blood, 109, 1401, 10.1182/blood-2005-12-015222 Cooper, 2002, Does treatment with intermittent infusions of anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?, Blood, 99, 1922, 10.1182/blood.V99.6.1922 Beck, 2005, Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials, J Pediatr, 147, 521, 10.1016/j.jpeds.2005.04.032 Nieswandt, 2000, Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice, Blood, 96, 2520, 10.1182/blood.V96.7.2520 Webster, 2006, Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa verus GPIba antibodies, Blood, 108, 943, 10.1182/blood-2005-06-009761 Tarantino, 2006, Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children, J Pediatr, 148, 489, 10.1016/j.jpeds.2005.11.019 Newman, 2001, A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura, Br J Haematol, 112, 1076, 10.1046/j.1365-2141.2001.02627.x Kjaersgaard, 2006, A review of anti-D treatment of childhood idiopathic thrombocytopenic purpura, Pediatr Blood Cancer, 47, 717, 10.1002/pbc.20996 Tarantino, 1999, Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin, J Pediatr, 134, 21, 10.1016/S0022-3476(99)70367-7 Kumar, 2005, Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura, Am J Hematol, 78, 181, 10.1002/ajh.20295 Fehr, 1982, Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin, N Engl J Med, 306, 1254, 10.1056/NEJM198205273062102 Siragam, 2006, Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells, Nat Med, 12, 688, 10.1038/nm1416 Kaneko, 2006, Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation, Science, 313, 670, 10.1126/science.1129594 Cooper, 2004, Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms, Br J Haematol, 124, 511, 10.1111/j.1365-2141.2004.04804.x Semple, 2002, Anti-D (WinRho SD) treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production, Am J Hematol, 69, 225, 10.1002/ajh.10065 Malinowska, 2001, Release of cytokines and soluble cytokine receptors after intravenous anti-D treatment in children with chronic thrombocytopenic purpura, Hematol J, 2, 242, 10.1038/sj.thj.6200106 Hansen, 2002, Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor, Thromb Haemost, 88, 898, 10.1055/s-0037-1613331 Vianelli, 2005, Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases, Haematologica, 90, 72 Bussel, 2006, Treatment of immune thrombocytopenic purpura in adults, Semin Hematol, 43, S3, 10.1053/j.seminhematol.2006.04.009 Arnold, 2007, Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura, Ann Intern Med, 146, 25, 10.7326/0003-4819-146-1-200701020-00006 Cooper, 2004, The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura, Br J Haematol, 125, 232, 10.1111/j.1365-2141.2004.04889.x Patel, 2006, Long term follow-up of patients with immune thrombocytopenic purpura (ITP) whose initial response to rituximab lasted a minimum of 1 year, Blood, 108, 479, 10.1182/blood.V108.11.479.479 Wang, 2005, Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment, J Pediatr, 146, 217, 10.1016/j.jpeds.2004.09.004 Bennet, 2006, Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura, Blood, 107, 2639, 10.1182/blood-2005-08-3518 Li, 2001, Thrombocytopenia caused by the development of antibodies to thrombopoietin, Blood, 98, 3241, 10.1182/blood.V98.12.3241 Basser, 2002, Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor, Blood, 99, 2599, 10.1182/blood.V99.7.2599 Kuter, 2007, New thrombopoietic growth factors, Blood, 109, 4607, 10.1182/blood-2006-10-019315 Jenkins, 2007, Phase I clinical study of eltrombopag, an oral, non-peptide thrombopoietin receptor agonist, Blood, 109, 4739, 10.1182/blood-2006-11-057968 Newland, 2006, An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura, Br J Haematol, 135, 547, 10.1111/j.1365-2141.2006.06339.x Bussel JB, Cheng G, Saleh M, et al. Eltrombopag, an oral platelet growth factor, for the treatment of patients with chronic idiopathic thrombocytopenic purpura. N Engl J Med, in press. McHutchison JG, Afdal NH, Dusheiko G, et al. Efficacy and safety of eltrombopag, an oral platelet growth factor, in subjects with HCV-associated thrombocytopenia: final results from a phase II multicenter, randomized placebo controlled, double-blind, dose ranging study. Program and abstracts of the 57th Annual Meeting of the American Association for the Study of Liver Diseases [abstract LB3]. Boston (MA); October 27–31, 2006. Cartron, 2002, Therapeutic activity of humanized anti-CD20 monoclonal activity and polymorphism in IgG Fc receptor FcγRIIIa gene, Blood, 99, 754, 10.1182/blood.V99.3.754 Nimmerjahn, 2007, The antiinflammatory activity of IgG: the intravenous IgG paradox, J Exp Med, 204, 11, 10.1084/jem.20061788